GLAXOSMITHKLINE $52.65

up +0.44


21/5/2013 04:21 PM  |  NYSE : GSK  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : 18% - GSK has underperformed the S&P 500 by 8%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. United Therapeutics' Lung Drug Breathes Again

    Investors Business Daily

  2. Odd, This: Big Pharma On Losing End of Pricing Dispute

    YCharts

  3. Pharma's Pay-to-Delay Deals Face Further Opposition: Senate Bill ...

    YCharts

  4. Stocks Stumble In Mixed Trade; Shutterfly Takes Wing

    Investors Business Daily

  5. Is My Doctor On the Payroll of Some Drug Maker? Now Easier to Find Out

    YCharts

  6. Pay-to-Delay Opponent, FTC Chief Leibowitz, Quits: Respite for Pharma?

    YCharts

  7. 2 Attractively Valued Blue Chips

    Benzinga

  8. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga

  9. AbbVie, Abbott Spinoff, Starts Life Near Top of Pharma Industry's ...

    YCharts

  10. FTC: Pay-to-Delay Pharma Deals Cover $8.3 Billion in Revenue

    YCharts

  11. Genpact Awarded Five-Year Contract Extension by GlaxoSmithKline

    Benzinga

  12. 4 Health Care ETFs Your Broker Forgot to Mention

    Benzinga

  13. Do Pharma Stocks Deserve Takeover Premiums? Read This First

    YCharts

  14. Parexel CEO Says 'New Era' For Pharma Has Arrived

    Investors Business Daily

  15. Illumina Stock Leaps On Roche Acquisition Reports

    Investors Business Daily

  16. GlaxoSmithKline

    Investors Business Daily

  17. With Influence Like This, You'd Expect Pharma Stocks to Do Better

    YCharts

  18. Amicus, Glaxo Release Top-Line Six-Month Primary Treatment Period ...

    Benzinga

  19. Dodge & Cox Explain Why They Are Overweight in Pharmaceuticals

    GuruFocus

  20. Benzinga's M&A Chatter for Tuesday December 11, 2012

    Benzinga

  21. Three More Defensive Stock Picks for 2013 (LLY, PFE, VTR)

    Benzinga

  22. A Look at Fortune's Health Care Picks for 2013 (ALGN, FMS, GILD)

    Benzinga

  23. Illumina Starring In Multiple Merger Dramas; Stock Up

    Investors Business Daily

  24. Warren Buffett's Best-Yielding Dividend Stocks

    GuruFocus

  25. Appeals Court Ruling on Off-Label Drug Marketing: What it Means

    YCharts

  26. The Other Healthcare Stocks of Warren Buffett

    GuruFocus

  27. How Big Pharma Might Get Its R&D Act Together

    YCharts

  28. Accenture Life Sciences Study: Worst of Pharma's Patent Cliff is ...

    YCharts

  29. If Only People Would Take Their Meds – Pharma Sales Might Double

    YCharts

  30. Vivus Stock Soars As Aetna Adds Qsymia To Coverage

    Investors Business Daily

  31. Advair, Glaxo's $4 Billion-a-Year Asthma Drug, Pushed in Key Study ...

    YCharts

  32. Dynavax: Little Stock With a Big Story – Plunge a Buy Opportunity?

    YCharts

  33. Benzinga's Volume Movers

    Benzinga

  34. Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New ...

    Benzinga

  35. Abraxane Cancer Trials Help Justify Celgene Buyout

    Investors Business Daily

  36. Yearly Low: GlaxoSmithKline (GSK)

    GuruFocus

  37. Big Pharma Gains Another Foe on Pay-to-Delay Deals: 31 State A.G.s ...

    YCharts

  38. An Anti-Psychotic Drug With its Own Issues: AstraZeneca's Seroquel ...

    YCharts

  39. More Trouble for Big Pharma Stocks: AMA Calls for an End to ...

    YCharts

  40. Pharma's Off-Label Violations Not Limited to the U.S.: Glaxo's ...

    YCharts

  41. GlaxoSmithKline's Phase 3 Malaria Vaccine Study Meets Primary Endpoint

    Benzinga

  42. Study on AZN's Seroquel Might Have Warned Pentagon Off Big Use of ...

    YCharts

  43. Mylan To Wall Street: Forget Patent Cliff, We'll Grow

    Investors Business Daily

  44. No-Go on Hepatitis Drug Patent in India: More Developing-Country ...

    YCharts

  45. Prestige climbs to 7-year high

    Investors Business Daily

  46. Charting Apple at $600: a PE Ratio Alongside Tired Old Companies ...

    YCharts

  47. Parexel Earnings Seen Growing 45% In Fiscal Q1

    Investors Business Daily

  48. More Quality Problems at Johnson & Johnson (Odious Details Omitted)

    YCharts

  49. Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

    Benzinga

  50. NuPathe Announces Closing of $28 Million Private Placement and ...

    Benzinga

  51. Global Squeeze on Pharma Prices Just Won't Ease Up: Canadians Iffy ...

    YCharts

  52. Ah, Geez, the Aussies, Too? Plush Patent Rights of Big Pharma ...

    YCharts

  53. Don't Call it Bribery  And Whatever it Was, Abbott Stopped Doing ...

    YCharts

  54. One Reason Novartis is Expected to Overtake Pfizer in Revenue: its ...

    YCharts

  55. Golly, Big Pharma, This Emerging Markets Strategy Isn't Looking So ...

    YCharts

  56. Array BioPharma CEO Favors Open, Unbiased Questions

    Investors Business Daily

  57. Pharma's March Into Emerging Markets Hits Yet Another Rough Spot

    YCharts

  58. Aeras Signs Agreement with GSK to Jointly Develop TB Vaccine

    Benzinga

  59. Big Pharma's Push Into Emerging Markets Meets More Resistance: ...

    YCharts

  60. Pharma's Pay-to-Delay Deals Boost Healthcare Costs (and Pharma ...

    YCharts

  61. Sarepta Stock Jumps On Muscular Dystrophy Drug Trial

    Investors Business Daily

  62. Merck's $1 Billion-a-Year Gardasil Vaccine Garners Another Safety ...

    YCharts

  63. The 20 Biggest Healthcare Dividend Payer

    GuruFocus

  64. Bad News For Pharma In World's Second-Biggest Market

    YCharts

  65. Thanks Mostly to J&J, Glaxo and Abbott, Feds and States Collecting ...

    YCharts

  66. Parexel Gets Sales, Profit Bump From Big Pharma

    Investors Business Daily

  67. A Big Part of the Pharma Pipeline is Struggling: Biotech Startups

    YCharts

  68. Pharma Profits Bottoming Out, Moody's Forecasts

    YCharts

  69. What's Pharma R&D Really Producing? Another Take on the Weak Drug ...

    YCharts

  70. Where in the World to Find Solid Dividends? Hint: Our Friends on ...

    YCharts

  71. Benzinga's Microcap Movers for Thursday September 13, 2012

    Benzinga

  72. Confused by Pharma Stocks' Hefty Dividends, Weak Drug Pipeline? ...

    YCharts

  73. Prestige Brand Sees The Ups And Downs Of Buyout Talk

    Investors Business Daily

  74. Seven Cheap Large-Caps Yielding Over 4%

    Benzinga

  75. Hi-Tech Pharm misses badly

    Investors Business Daily

  76. Hi-Tech Pharmacal Stock Plunges On Big Q1 Shortfall

    Investors Business Daily

  77. Stocks Flat on Mixed Data

    At Market Intelligence Center

  78. Benzinga's Top Downgrades

    Benzinga

  79. Pay-to-Delay Deals by Big Pharma Could be Headed to Supreme Court

    YCharts

  80. Health Care Stocks: Utility-Like Dividend Yields, Without the ...

    YCharts

  81. GSK and Theravance Announce Completion of the Phase III Programme ...

    Benzinga

  82. A Peek Into The Market Before The Trading Starts

    Benzinga

  83. UPDATE: JP Morgan Downgrades GlaxoSmithKline to Underweight; ...

    Benzinga

  84. Parkinson's Drug Awaits OK While ADHD Lifts Impax Now

    Investors Business Daily

  85. Can Big Pharma Stocks be Saved by Emerging Markets? Ex-Pfizer ...

    YCharts

  86. UPDATE: Jefferies Downgrades GlaxoSmithKline to Hold on Margin ...

    Benzinga

  87. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With ...

    Benzinga

  88. Four Investment Options Presented by Obesity and Related Health ...

    YCharts

  89. 10 Best Yielding Drug Manufacturing Stocks

    GuruFocus

  90. GlaxoSmithKline Will Pay $14.25/Share to Remaining Human Genome ...

    Benzinga

  91. Biotechs In Motion As New Drug Pipeline Brims

    Investors Business Daily

  92. Sales Of Januvia And Gardasil Boost Merck's Earnings

    Investors Business Daily

  93. Bristol-Meyers, Glaxo Post Mixed Results For Q2

    Investors Business Daily

  94. Bristol-Myers, Glaxo Post Mixed Results For Q2

    Investors Business Daily

  95. Ligand Partner GlaxoSmithKline Announces Priority Review for ...

    Benzinga

  96. 3 Big Pharmas Reporting Quarterly Earnings Wednesday

    Investors Business Daily

  97. Can Jazz Pharmaceuticals Lift The Ethical Drug Group?

    Investors Business Daily

  98. FDA's Truvada Approval Seals Gilead's Leading Position

    GuruFocus

  99. Glaxo, Par Join M&A Meetup

    Investors Business Daily

  100. GlaxoSmithKline PLC (GSK) Rises 0.7% After Human Genome Sciences ...

    At Market Intelligence Center
People viewing GSK also viewed: , , , , , ,
Marketplace
Trading Center